Top

Published in:

01-01-2011 | Epidemiology

Lack of association between HER2 codon 655 polymorphism and breast cancer susceptibility: meta-analysis of 22 studies involving 19,341 subjects

Authors: Yanlei Ma, Jianjun Yang, Peng Zhang, Zhihua Liu, Zhe Yang, Huanlong Qin

Published in: Breast Cancer Research and Treatment | Issue 1/2011

Abstract

Epidemiological studies have investigated the association between HER2 codon 655 polymorphism and breast cancer susceptibility. However, the results are still inconclusive. To obtain a more precise estimation of the relationship, this meta-analysis was performed. A total of 22 studies including 9,209 cases and 10,132 controls were collected. The strength of association between HER2 codon 655 polymorphism and breast cancer susceptibility was assessed by calculating crude ORs with 95% CIs. When all the 22 studies were pooled into the meta-analysis, there was no evidence for significant association between HER2 codon 655 polymorphism and breast cancer susceptibility (for Val/Ile vs. Ile/Ile: OR = 1.069, 95% CI = 0.976–1.172; for Val/Val vs. Ile/Ile: OR = 1.191, 95% CI = 0.922–1.538; for dominant model: OR = 1.093, 95% CI = 0.991–1.206; for recessive model: OR = 1.141, 95% CI = 0.902–1.444). In the subgroup analysis by the source of controls and ethnicity, no significant increased risk was found in all genetic models. However, the current results indicated the modest association between the HER2 Ile655Val polymorphism and Asian population (Val/Ile vs. Ile/Ile: OR = 1.207, CI = 1.006–1.450). In summary, the meta-analysis suggests that HER2 codon 655 polymorphism is not associated with the increased breast cancer risk.

Mackay A, Jones C, Dexter T, Silva RL, Bulmer K, Jones A, Simpson P, Harris RA, Jat PS, Neville AM, Reis LF, Lakhani SR, O’Hare MJ (2003) cDNA microarray analysis of genes associated with ERBB2 (HER/neu) overexpression in human mammary luminal epithelial cells. Oncogene 22:2680–2688CrossRefPubMed

Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358:1389–1399CrossRef

Turnbull C, Rahman N (2008) Genetic predisposition to breast cancer: past, present and future. Annu Rev Genomics Hum Genet 9:321–345CrossRefPubMed

Wang YC, Chen CY, Chen SK, Chang YY, Lin P (1999) P53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. Clin Cancer Res 5:129–134PubMed

Baselga J, Norton L (2002) Focus on breast cancer. Cancer Cell 1:319–322CrossRefPubMed

Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA (1984) The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312:513–516CrossRefPubMed

King CR, Kraus MH, Aaronson SA (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974–976CrossRefPubMed

Bargmann CI, Hung MC, Weinberg RA (1986) The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319:226–230CrossRefPubMed

Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T (1986) The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644–1646CrossRefPubMed

10.

Hynes NE, Stern DF (1994) The biology of erbB-2/neu/HER2 and its role in cancer. Biochim Biophys Acta 1198:165–184PubMed

11.

Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127–137CrossRefPubMed

12.

McKean-Cowdin R, Kolonel LN, Press MF, Pike MC, Henderson BE (2001) Germline HER-2 variant and breast cancer risk by stage of disease. Cancer Res 61:8393–8394PubMed

13.

Tommasi S, Fedele V, Crapolicchio A, Bellizzi A, Paradiso A, Reshkin SJ (2003) ErbB2 and the antimetastatic nm23/NDP kinase in regulating serum induced breast cancer invasion. Int J Mol Med 12:131–134PubMed

14.

Walker RA, Gullick WJ, Varley JM (1989) An evaluation of immunoreactivity for c-erb B2 protein as a marker of poor short-term prognosis in breast cancer. Br J Cancer 60:426–429PubMed

15.

Paik S, Bryant J, Tan-Chiu E, Yothers G, Park C, Wickerham DL, Wolmark N (2000) HER2 and choice of adjuvant chemotherapy for breast cancer. National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 92:1991–1998CrossRefPubMed

16.

Papewalis J, Nikitin AY, Rajewsky MF (1991) G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene. Nucleic Acids Res 19:5452CrossRefPubMed

17.

Akisik E, Dalay N (2004) Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk. Exp Mol Pathol 76:260–263CrossRefPubMed

18.

An HJ, Kim NK, Oh D et al (2005) Her2 genotype and breast cancer progression in Korean women. Pathol Int 55:48–52CrossRefPubMed

19.

Baxter SW, Campbell IG (2001) Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 93:557–559CrossRefPubMed

20.

Benusiglio PR, Pharoah PD, Smith PL et al (2006) HapMapbased study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer. Br J Cancer 95:1689–1695CrossRefPubMed

21.

Cox DG, Hankinson SE, Hunter DJ (2005) The erbB2/HER2/neu receptor polymorphism Ile655Val and breast cancer risk. Pharmacogenet Genomics 15:447–450CrossRefPubMed

22.

Frank B, Hemminki K, Wirtenberger M et al (2005) The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. Carcinogenesis 26:643–647CrossRefPubMed

23.

Hishida A, Hamajima N, Iwata H et al (2002) Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 94:1807–1808PubMed

24.

Kalemi TG, Lambropoulos AF, Gueorguiev M et al (2005) The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett 222:57–65CrossRefPubMed

25.

Kallel I, Kharrat N, Al-fadhly S, Rebai M, Khabir A, Boudawara TS, Rebaï A (2010) HER2 polymorphisms and breast cancer in Tunisian women. Genet Test Mol Biomarkers 14:29–35CrossRefPubMed

26.

Kamali-Sarvestani E, Talei AR, Merat A (2004) Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women. Cancer Lett 215:83–87PubMed

27.

Kara N, Karakus N, Ulusoy AN, Ozaslan C, Gungor B, Bagci H (2010) P53 codon 72 and HER2 codon 655 polymorphisms in Turkish breast cancer patients. DNA Cell Biol. doi:10.1089/dna.2009.0995 PubMed

28.

Keshava C, McCanlies EC, Keshava N, Wolff MS, Weston A (2001) Distribution of HER2(V655) genotypes in breast cancer cases and controls in the United States. Cancer Lett 173:37–41CrossRefPubMed

29.

Lee SC, Hou MF, Hsieh PC, Wu SH, Hou LA, Ma H, Tsai SM, Tsai LY (2008) A case-control study of the HER2 Ile655Val polymorphism and risk of breast cancer in Taiwan. Clin Biochem 41:121–125CrossRefPubMed

30.

Montgomery KG, Gertig DM, Baxter SW, Milne RL, Dite GS, McCredie MR, Giles GG, Southey MC, Hopper JL, Campbell IG (2003) The HER2 I655 V polymorphism and risk of breast cancer in women <age 40 years. Cancer Epidemiol Biomarkers Prev 12:1109–1111PubMed

31.

Naidu R, Yip CH, Taib NA (2008) Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases. Neoplasma 55:87–95PubMed

32.

Nelson SE, Gould MN, Hampton JM (2005) A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer. Breast Cancer Res 7:R357–R364CrossRefPubMed

33.

Papadopoulou E, Simopoulos K, Tripsianis G, Tentes I, Anagnostopoulos K, Sivridis E, Galazios G, Kortsaris A (2007) Allelic imbalance of HER-2 codon 655 polymorphism among different religious/ethnic populations of northern Greece and its association with the development and the malignant phenotype of breast cancer. Neoplasma 54:365–373PubMed

34.

Pinto D, Vasconcelos A, Costa S, Pereira D, Rodrigues H, Lopes C, Medeiros R (2004) HER2 polymorphism and breast cancer risk in Portugal. Eur J Cancer Prev 13:177–181CrossRefPubMed

35.

Tommasi S, Fedele V, Lacalamita R, Bruno M, Schittulli F, Ginzinger D, Scott G, Eppenberger-Castori S, Calistri D, Casadei S, Seymour I, Longo S, Giannelli G, Pilato B, Simone G, Benz CC, Paradiso A (2007) 655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCA1 alterations. Cell Oncol 29:241–248PubMed

36.

Wang-Gohrke S, Chang-Claude J (2001) Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 93:1657–1659CrossRefPubMed

37.

Xie D, Shu XO, Deng Z, Wen WQ, Creek KE, Dai Q, Gao YT, Jin F, Zheng W (2000) Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 92:412–417CrossRefPubMed

38.

Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMed

39.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMed

40.

Tobias A (1999) Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 8:15–17

41.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMed

42.

Qiu L-X, Yao L, Mao C, Yu K-D, Zhan P, Chen B, Yuan H, Zhang J, Xue K, Hu X-C (2010) Lack of association of CYP1A2-164 A/C polymorphism with breast cancer susceptibility: a meta-analysis involving 17,600 subjects. Breast Cancer Res Treat. doi:10.1007/s10549-009-0731-4

43.

Zúbor P, Vojvodová A, Danko J, Kajo K, Szunyogh N, Lasabová Z, Biringer K, Visnovský J, Dókus K, Galajda P, Plank L (2006) HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case-control study in Slovakia. Neoplasma 53(1):49–55PubMed

Title: Lack of association between HER2 codon 655 polymorphism and breast cancer susceptibility: meta-analysis of 22 studies involving 19,341 subjects
Authors: Yanlei Ma
Jianjun Yang
Peng Zhang
Zhihua Liu
Zhe Yang
Huanlong Qin
Publication date: 01-01-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-0965-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Pure flat epithelial atypia (DIN 1a) on core needle biopsy: study of 60 biopsies with follow-up surgical excision

Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells

Same data sources, different pooled analysis result: the ongoing uncertainty in the subgroup analysis of RAD51 135G/C polymorphism and breast cancer risk

Lack of an association between AURKA T91A polymorphisms and breast cancer: a meta-analysis involving 32,141 subjects

Presence of MMTV-like env gene sequences in human breast cancer

Nicotine-induced human breast cancer cell proliferation attenuated by garcinol through down-regulation of the nicotinic receptor and cyclin D3 proteins

Keynote webinar | Spotlight on antibody–drug conjugates in cancer